

**2005 HEPATITIS C INTERACTIVE EDUCATIONAL PROGRAM
SERIES:**

**“Managing, Caring and Treating Patients
Coinfected with HCV, HBV and HIV”**

April 25-26th, 2005

Place: Sheraton Fisherman’s Wharf, 2500 Mason Street, San Francisco, CA

Purpose: The management and care of HIV positive patients with HCV or HBV is changing due to a number of factors. First, liver disease is now the leading cause of death in HIV positive patients since the HAART era. Second, HIV infection may impact the actual progression of liver disease and third, there have been recent advances in HCV and HBV therapy for both mono and co-infected patients. It is these factors that have made it increasingly important that all patients infected with HIV and HCV or HBV be considered for treatment. The need to educate and develop strategies to more effectively manage and care for the co-infected population also raises additional considerations: the majority of HIV-HCV infected patients identify their HIV provider as their primary care provider; barriers to treatment in coinfecting patients have traditionally included nonadherence, mental health and substance use issues, advanced liver or HIV disease, as well as other medical comorbidities. Other areas that are unique to this group involve screening, monitoring, drug-drug interactions, HBV coinfection and even the potential for liver transplant. This program is designed to address these issues.

Goal: The goal of this 2 day interactive program is to provide participants with strategies and resources to optimize their management and care of coinfecting patients. The program will include topics such as: the Natural History of HBV, HCV and HIV, HCV; HBV and HIV screening and assessment, Current HCV Tx Recommendations and Therapies, Drug-Drug Interactions, Monitoring for Adverse Events, Liver Transplantation. It will provide practical tips and resources regarding mental health and substance abuse issues, patient adherence and general side effect management and other potential barriers that may impact the coinfecting patient. Case discussions and structured Q & A sessions will be integrated into the program, as well as networking with other program participants and 1-1 time with different program faculty through the lunch box sessions.

Outcome Objectives :

After attending this program, participants will be able to:

1. Describe the natural history and progression of HCV, HBV and HIV coinfection;
2. Develop an individualized plan for their facility / practice for screening and assessing patients with coinfection, including preventative care such as vaccinations;
3. Identify and describe current treatment strategies available for HIV and HCV coinfecting patients;
4. List and identify possible drug-drug interactions between HCV and HAART treatments;
5. Identify current screening, management and treatment strategies available for HIV-HBV patients;
6. Describe strategies to monitor coinfecting patients on HCV therapy, including tools to minimize adverse events and support adherence;
7. Identify screening tools and management strategies for other potential barriers to care, including mental health and substance issues;
8. Identify possible candidates for liver transplantation.

Target Audience: This is designed for both HIV and HCV providers with patients with HIV and/or HCV or HBV coinfection working in public health, correctional, veteran, HMOs, University, private or other clinical settings. It is also designed for primary care providers in infectious disease practice settings such as nurse practitioners, clinical pharmacists, general internal medicine clinicians and other providers working directly with coinfecting patients.

Program Capacity: Space is limited to only 70 persons to facilitate participant and faculty interaction and networking.

Program Chairs: **Paul Volberding, MD, Professor of Medicine, Chief, Medical Service**
Department of Medicine, University of California-San Francisco;
Veterans Administration Medical Center
Teresa Wright, MD, Professor of Medicine, Chief, Gastroenterology Section
Department of Medicine, University of California-San Francisco;
Veterans Administration Medical Center

Program Director: **Sue Currie, MA (Moderator), Specialist**
Department of Medicine, University of California-San Francisco

Faculty: (proposed) **Maurizio Bonacini, MD, Associate Clinical Professor of Medicine**
Department of Medicine, University of California-San Francisco
Rena Fox, MD, Assistant Clinical Professor of Medicine
Department of General Internal Medicine, University of California-San Francisco

Brian Klein, MA, LMSW
Hepatitis C Action and Advocacy Coalition

Alexander Monto, MD, Assistant Clinical Professor of Medicine
Department of Medicine, University of California-San Francisco

Valerie Robb, RN, Clinical Nurse, UCSF
San Francisco General Hospital

Karen Seal, MD, MPH, Assistant Professor of Medicine
Department of Medicine, University of California-San Francisco

Peter Stock, MD, Associate Professor, Surgery
Department of Medicine, University of California-San Francisco

Phyllis Tien, MD, Assistant Professor of Medicine
Department of Medicine, University of California-San Francisco;

Paul Volberding, MD, Professor of Medicine, Chief, Medical Service
Department of Medicine, University of California-San Francisco;
Veterans Administration Medical Center

Teresa Wright, MD, Professor of Medicine, Chief, Gastroenterology Section
Department of Medicine, University of California-San Francisco;
Veterans Administration Medical Center

Helen Yee, PharmD, Assistant Clinical Professor
Department of Clinical Pharmacy, University of California-San Francisco

Report of Training: It is the program participant's responsibility to ensure that this training is documented in the appropriate location according to his/her locally prescribed process.

Continuing Education Credits: MD & PA: The Minneapolis GRECC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The GRECC takes responsibility for the scientific integrity of this CME activity. The GRECC designates this CME activity for maximum of 13.0 credit hours in Category #1 of the Physician's Recognition Award of the American Medical Association.
Psychologists: The Minneapolis GRECC is approved by the American Psychological Association to offer continuing education for psychologists. The Minneapolis GRECC maintains responsibility for the educational content of the program and is offering this activity for a maximum of 14.5 continuing education hours for psychologists.
Others: This educational activity has been planned and implemented following the administrative and educational design essential areas and policies of most professional organizations. Registrants attending this activity may submit this certificate along with the course content to the appropriate professional association or state licensing agency for recognition of a maximum of 14.5 continuing education contact hours.

This program is supported in part by unrestricted educational grants from:

Program Schedule (Draft 03/02/05)

Day One: Monday, April 25th, 2005

8:15am – 8:45 am	Program Registration & Syllabus Pick-up and Continental Breakfast	
8:45am – 9:00am	Welcome, Program Logistics	Paul Volberding, MD & Teresa Wright, MD – Co-chairs
	Module #1: Overview	
9:00am – 9:20 am	Epidemiology of HCV, HBV and HIV Coinfection	Rena Fox, MD
9:25am – 9:50 am	Overview of HIV Therapy	Paul Volberding, MD
9:50am -10:00am	BREAK	
10:00am –11:10am	The Role of HIV in the Management of HCV Disease AND the Role of HCV in the Management of HIV Disease	Alex Monto, MD
	Module #2: Screening and Assessments for HCV/HIV	
11:15am - 11:40am	HCV Screening and Assessment for HCV Therapy in the Coinfected Patient	Karen Seal, MD, MPH
11:40am-11:55pm	Case #1 and Discussion	Morning Panel
12:10pm – 1:30pm	Faculty and Participant Networking Lunch	Faculty “Hosts” at Each Table
1:30pm – 1:45pm	BREAK	
	Module #3: Current Therapies and Potential Issues for HIV/HCV Patients	
1:45pm – 2:30pm	Current Therapies for Coinfected Patients & Special Considerations for Coinfected Patients: Tx Responses, duration and CD4s.	Maurizio Bonacini, MD
2:35pm – 3:20pm	Hepatotoxicity of HAART, Immune Reconstitution & Drug-Drug Interactions	Phyllis Tien, MD
3:25pm – 4:00pm	Case #2 and #3, Q & A	Panel
4:00pm – 4:15pm	Day One Program Wrap-up	Sue Currie

Day Two: Tuesday, April 26th, 2005

7:45am – 8:15 am	Day 2 Program Review and Continental Breakfast	Sue Currie, MA
	Module #4: HBV: Current Therapies for HIV/HBV	
8:15am – 9:00am	Current HBV Treatment Options for the Coinfected Patient	Teresa Wright, MD
9:00am – 9:30am	Special considerations for the HBV/HIV Coinfected Patients	Teresa Wright, MD
9:30am – 9:45am	Case # 4	Panel
9:45am – 10:05am	BREAK (and Check-out for non-local participants)	
	Module #5: Patient Care and Potential Barriers to Adherence	
10:05am – 10:25am	Mental health, substance use and other potential barriers to adherence	Val Robb, NP
10:30am – 11:00 am	Monitoring and Management of Tx-related Side Effects	Helen Yee, PharmD
11:05am – 11:45am	“Patient Care Management Side Effects and Adherence”	Brian Klein and Patient Panel
11:45am – 12:20pm	Module #6: Special Topic: Organ Transplantation for HIV positive persons	Peter Stock, MD
12:20pm – 1:00pm	Faculty and Participant Networking Box Lunch	Faculty Participants
1:00pm – 1:15pm	Program Wrap-up and Evaluation	Sue Currie, MA